1 1 Review Experience in Evaluating Predictive Biomarkers – Design and Analysis Considerations Yuan-Li Shen, Dr. P.H. U.S. Food and Drug Administration.
Introduction Dr Alan Haycox Reader in Health Economics Health Economics Unit University of Liverpool Management School Onco-Pharmacoeconomy Training Course.
Adjuvant Breast Cancer Therapy An Analysis of Current Treatment Paradigms Mark D. Pegram, MD UCLA/Jonsson Comprehensive Cancer Center.
Adjuvant Breast Cancer Therapy An Analysis of Current Treatment Paradigms
STAR. 2 NSABP P-1 Trial Results: Age > 50 Category TamoxifenPlacebo ARD RR(95% CI) n 4010 IR n 4008 IR Breast Cancer Invasive Invasive Non-invasive Non-invasive51253.211.58107326.802.04+3.59+0.46.
Amylou C. Dueck (Mayo Clinic) – Task 7 Lead
Analysis & Display of Haematology & Biochemistry Data for Oncology Patients Penny Ross University of Portsmouth & Portsmouth Hospitals Friends of Radiotherapy.
Predictive Analysis of Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute .
